.png)
OBJECTIVE: Schizophrenia is a neurodegenerative and neurodevelopmental disorder. For this reason, it is important to determine the level of markers that are neuroprotective and have been altered in other neurodegenerative diseases in inspecting the etiology of schizophrenia. Secretagogin (SCGN), is a member of Calcium (Ca) binding proteins and thought to have a neuroprotective effect. In this study, we aimed to compare the level of secretagogin (SCGN) between age and gender-matched schizophrenia and control group.
METHODS: Fifty-three patients with schizophrenia who applied to outpatient clinics of our hospital and 37 healthy controls included in the study. Schizophrenia diagnoses of the patients were verified using the DSM-5 criteria. Serum secretagogin levels were measured with the enzyme-linked immunosorbent assay (ELISA) test. The Body Mass Index (BMI) of the patient group was measured.
RESULTS: There was no significant difference between the controls and patients in terms of fasting blood glucose and insulin levels. We did not find any difference in terms of the levels of serum secretagogin between patients with schizophrenia and controls. Negative correlations were found between the level of secretagogin and PANSS positive score, PANSS negative score, PANSS general psychopathology score.
CONCLUSION: There is increasing evidence that SCGN may play a role in central nervous system (CNS) activity. Future studies might help to explicitly present the relationship between secretagogin and schizophrenia